KLBF Stock: Kalbe Farma Profile, Business, Performance and Risks

Kalbe Farma is an Indonesian pharmaceutical company based in Jakarta that has operated since 1966. Through dozens of subsidiaries, it spans prescription drugs, consumer health products, nutrition, distribution, clinics and laboratories, plus an international business arm. Its shares trade on the Indonesia Stock Exchange under the ticker KLBF.

KLBF stock summary

As of October 23, 2026:

Kalbe Farma's business

Kalbe Farma runs four main business lines. First is prescription pharmaceuticals through subsidiaries like Dankos Farma, Hexpharm Jaya, and Finusolprima Farma. Second is consumer health products through Bintang Toedjoe, maker of Extra Joss, an energy drink launched in 1994.

Third is the nutrition business consolidated under Sanghiang Perkasa, plus joint ventures Kalbe Milko Indonesia and Kalbe Morinaga Indonesia for dairy and liquid nutrition products. Fourth is distribution and logistics through Enseval Putera Megatrading and Millennium Pharmacon International, two companies that are also separately listed on the IDX.

Beyond those four segments, Kalbe also runs healthcare services through Mitrasana clinics, RenaMedika hemodialysis clinics, and Kalgen Innolab clinical laboratories, the latter established with Japanese partners Hoken Kagaku Kenkyujo and Toyota Tsusho. The company is also active in vaccine distribution and vaccination programs for the elderly, the general public, and employees.

On the international front, Kalbe operates several overseas entities, including Innogene Kalbiotech Pte. Ltd., DHG Pharmaceutical Joint Stock Company, and a 49% stake in Thailand's Alliance Pharma acquired in May 2024. According to Wikipedia, Kalbe's products are sold in 43 countries across 5 continents.

Brief history and IPO

Kalbe Farma was founded in September 1966 by six siblings from Tegal, Central Java: Khouw Lip Tjoen, Khouw Lip Hiang (Theresia Harsini Setiady), Khouw Lip Swan, Khouw Lip Boen (Boenjamin Setiawan), Khouw Lip Hwa (Maria Karmila Angkasa), and Khouw Lip Bing (Fransiscus Bing Aryanto). Of the six, only Boenjamin Setiawan, who handled research and development, and Bing Aryanto, who managed finance and marketing, were directly involved in day-to-day operations.

The business started in a garage at the founder's home in North Jakarta before being formally established. Early expansion came through the 1977 acquisition of Dankos Laboratories to strengthen its pharmaceutical line, followed by the acquisitions of Bintang Toedjoe and Hexpharm Jaya in 1985.

Kalbe Farma officially listed on the stock exchange in 1991, following two subsidiaries, Igar Jaya and Dankos Laboratories, which had listed earlier in 1989. Enseval Putera Megatrading followed with its own listing in 1994, the same year Extra Joss launched. After going public, the company kept acquiring and forming new joint ventures: Sanghiang Perkasa (1992), the Woods' brand and an 80% stake in Saka Farma Laboratories (1997), a full stake in Hale International (2012), and Kalbe Genexine Biologics and Kalbe Blackmores Nutrition in 2015. In 2018, President Joko Widodo inaugurated a raw material and biological products plant operated by Kalbio Global Medika in Cikarang.

Shareholders and management

The sources we checked only mention the company's founders and don't include current shareholder composition or the latest board of directors and commissioners. For up-to-date ownership and management data, check Kalbe Farma's latest annual report or disclosures on idx.co.id.

Recent financial performance

The sources we checked don't include revenue, net profit, or growth figures for Kalbe Farma's recent periods. To review official financial performance, including quarterly and annual reports, readers can access Kalbe Farma's financial statements directly on idx.co.id.

Dividends

There's no data on Kalbe Farma's dividend policy or payout history in the sources we checked. Dividend information is typically announced through the Annual General Meeting of Shareholders (RUPS) and can be checked via the dividend calendar on idx.co.id or the company's annual report.

KLBF stock price movement

As of October 23, 2026, KLBF traded at Rp720 per share. That's relatively close to the bottom of its 52-week range (Rp630-Rp1,345), far from its highest price over the past year.

Over the past month the price fell 2.0%, while over three months it was essentially flat at 0.0%. But looking back a full year, the stock has corrected 39.2%, a fairly steep decline relative to its own price range.

Average daily trading volume over the past three months stood at 74.43 million shares, suggesting the stock remains actively traded despite the price pressure.

Recent news and catalysts

Over the past few weeks, KLBF has repeatedly appeared on local brokerage trading idea lists amid volatility in Indonesia's benchmark index. On October 22, 2026, Liputan6.com reported that BNI Sekuritas' Head of Retail Research, Fanny Suherman, included KLBF in a trading idea list alongside AMMN, DSSA, INCO, MAPA, and PGEO, on a day when the IHSG was expected to trade sideways with a weakening bias after closing up 0.94% amid Rp528 billion in foreign net selling. Stocks most sold by foreign investors that day included BMRI, ANTM, TLKM, BBRI, and AADI.

Two days earlier, on October 20, 2026, KLBF also appeared in BNI Sekuritas' trading idea list alongside EMAS, TAPG, ESSA, INKP, and ERAA, according to reports from topbusiness.id and Liputan6.com. At the time, the IHSG had just dropped 3.64% amid roughly Rp2.28 trillion in foreign net selling, against a backdrop of uncertainty around MSCI rebalancing. Suherman noted the IHSG could see a technical rebound toward the 5,020-5,160 range with support at 4,750-4,850, but suggested investors use that window to take profit first since the risk of further correction remained open.

Separately, a TradingView article citing Kontan, dated September 16, 2026, carried a headline about Kalbe Farma's plan to conduct a share buyback. The excerpt we reviewed didn't include details on the amount of funds, number of shares, or the buyback's timeline. Investors wanting confirmation on this plan should check Kalbe Farma's official disclosures on idx.co.id.

What it means for investors

KLBF's current price of Rp720 sits only about Rp90 above its 52-week low of Rp630. Its 52-week high, Rp1,345, is nearly double the current price. That range is a useful marker for gauging how far the stock has moved from its peak.

A few concrete things worth tracking going forward:

• The Rp630 and Rp1,345 levels as the lower and upper bounds of the 52-week range. A break beyond either level typically signals something meaningful for the medium-term trend.
• Daily trading volume, which averaged 74.43 million shares over the past three months. A sharp spike in volume alongside a price move usually signals stronger-than-usual buying or selling interest.
• Clarity on the buyback plan referenced by TradingView/Kontan on September 16, 2026. As of this writing, details on the value and number of shares to be repurchased remain unconfirmed in the sources we checked. An official IDX disclosure will determine its impact on shares outstanding.
• The next quarterly financial report, which isn't covered in these sources. That report will be an important reference for assessing whether the 39.2% one-year price decline tracks business performance or reflects broader market sentiment.
• Foreign net buy/sell flows and the broader IHSG direction, given that KLBF has repeatedly shown up on trading idea lists during periods when the IHSG faced foreign net selling and MSCI rebalancing uncertainty in mid-October 2026.

All of the above are meant as things to watch, not signals for when to enter or exit this stock.

Competitors on the IDX

A few other pharmaceutical and healthcare issuers on the IDX often compared with Kalbe Farma:

• SIDO (Industri Jamu dan Farmasi Sido Muncul) — focuses more on herbal remedies and health drinks rather than prescription drugs.
• TSPC (Tempo Scan Pacific) — another major pharmaceutical player with a broad range of everyday consumer products.
• PYFA (Pyridam Farma) — a pharmaceutical producer operating at a much smaller scale than Kalbe.
• INAF (Indofarma) — a state-owned pharmaceutical company focused on generic drugs and medical equipment.

Risks

Some risks worth monitoring for KLBF stock:

• Long-term price pressure. KLBF has fallen 39.2% over the past year and sits near its 52-week low of Rp630, reflecting persistently weak market sentiment toward the stock.
• Macro and foreign flow sentiment. Several brokerage reports noted broader IHSG pressure from foreign net selling and MSCI rebalancing uncertainty in October 2026, factors that could spill over into blue-chip names including KLBF.
• Healthcare sector regulation. As a pharmaceutical company, Kalbe is exposed to drug pricing policy, BPOM regulations, and health financing schemes like BPJS that can affect margins.
• Group complexity. Kalbe operates dozens of subsidiaries across pharmaceuticals, nutrition, distribution, healthcare services, and international business, a broad structure that also adds consolidation and risk management complexity.
• Limited recent financial data in these sources. This article doesn't include current revenue or net profit figures, so investors should check official financial statements before assessing valuation.
• An unclear buyback plan. If a share buyback is indeed in the works, its impact on outstanding shares and price needs confirmation through official announcements, not just a news headline.

How to buy KLBF stock

One lot of KLBF shares consists of 100 shares. At Rp720 per share as of October 23, 2026, one lot is worth roughly Rp72,000 before brokerage fees.

To buy KLBF shares, the basic step is opening a securities account with a brokerage licensed by Indonesia's Financial Services Authority (OJK) and registered as an IDX exchange member. Once the account is active and funded, investors can place a buy order for KLBF through that broker's trading app at the prevailing market price.

This article is written for informational purposes only and is not a recommendation to buy or sell KLBF stock.